Clinical Trial Update: CD123 Redirected Autologous T Cells for AML [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial assessing CD123-targeted autologous T cells for relapsed or refractory acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD123 Redirected Autologous T Cells (CD123 CAR-T cells)

Snippet

Sponsor: University of Pennsylvania | Conditions: Relapsed or Refractory Acute Myeloid Leukemia | EARLY_Phase 1 | Status: TERMINATED